 MIRAMAR, Fla., Nov. 03, 2020 GLOBE NEWSWIRE -- NuGenerex Immuno-Oncology NGIO, a subsidiary of Generex Biotechnology Corporation erex.com OTCQB:GNBT is pleased to announce that the company has launched its new corporate website to provide investors with information on the NGIO mission, management, and pipeline for the Ii-Key vaccine platform for cancer and infectious disease. You can also learn about the companys ongoing SARS-CoV-2 vaccine development program and collaborations. You can visit the site at . 